{
    "Trade/Device Name(s)": [
        "EliA RNA Pol III"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K202541",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070066"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYO"
    ],
    "Summary Letter Date": "March 4, 2021",
    "Summary Letter Received Date": "March 5, 2021",
    "Submission Date": "September 3, 2021",
    "Regulation Number(s)": [
        "21 CFR 866.5100"
    ],
    "Regulation Name(s)": [
        "Antinuclear Antibody Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "IgG autoantibodies to RNA polymerase III"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Phadia 250",
        "Phadia 2500 E-module",
        "Phadia 5000 E-module"
    ],
    "Method(s)/Technology(ies)": [
        "Solid-phase fluoroenzymeimmunoassay"
    ],
    "Methodologies": [
        "Fluorescence immunoassay",
        "Semi-quantitative antibody detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Control",
        "Calibrator",
        "Automated system"
    ],
    "Document Summary": "FDA 510(k) summary for EliA RNA Pol III automated fluoroenzymeimmunoassay for detection of IgG autoantibodies to RNA polymerase III for systemic sclerosis diagnosis",
    "Indications for Use Summary": "In vitro semi-quantitative measurement of IgG antibodies to RNA polymerase III in human serum as an aid in diagnosing systemic sclerosis (diffuse form), used in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}